Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...

Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years[1] New data from six-year study validate Aclasta safety profile and ...

Study of more than 2,100 patients who suffered a hip fracture shows 35% reduction in subsequent osteoporotic fractures in Aclasta-treated patients Results published in The New England Journal of ...

New long-term data for Novartis’ once-yearly osteoporosis jab Aclasta/Reclast have cemented its safety and efficacy profile, showing that the drug preserves bone mass and slashes the risk of new spine ...

Patients in the UK will this week get access to Novartis’ annual postmenopausal osteoporosis drug Aclasta, following its European approval last Friday. Patients in the UK will this week get access to ...

01 February 2009Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Amman - Jordan - Aclasta (zoledronic acid 5 ...

LONDON (MarketWatch) -- Swiss drugmaker Novartis said Friday that its Aclasta medicine has been approved in the European Union to treat men and postmenopausal women with osteoporosis caused by ...

From the good news, bad news file: Novartis got the EU's approval to sell its new osteoporosis drug Aclasta, known in the U.S. as Reclast. Reclast got the FDA's nod six weeks ago, and analysts are ...

April 25, 2005 — Health Canada has approved levonorgestrel emergency contraceptive for sale without a prescription to women aged 16 years and older, and an oral spray derived from components of the ...

Novartis AG said Friday that the European Union approved its bone drug Aclasta, a treatment that needs to be taken only once a year. Switzerland-based Novartis said the EU regulator approved Aclasta ...